Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 20/20 | 0.72 |
| ▸ | MAOA | P21397 | 3/20 | 0.57 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | LOXL3 | P58215 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19259594 | 0.89 | LOXL2 (0.71) | LOXL2MAOAAOC3MAOBKCNH2 | |
| SCHEMBL19259932 | 0.89 | LOXL2 (0.72) | LOXL2MAOAAOC3MAOBKCNH2 | |
| SCHEMBL28641865 | 0.88 | LOXL2 (0.67) | LOXL2MAOAAOC3MAOBKCNH2 | |
| SCHEMBL29971073 | 0.88 | LOXL2 (0.67) | LOXL2MAOAAOC3MAOBKCNH2 | |
| SCHEMBL19274862 | 0.84 | LOXL2 (1.00) | LOXL2MAOAAOC3MAOBKCNH2 | |
| Hydrochloric Acid SCHEMBL19259760 | 0.83 | LOXL2 (1.00) | LOXL2MAOAAOC3MAOBKCNH2 | |
| SCHEMBL29971568 | 0.80 | LOXL2 (0.63) | LOXL2MAOAAOC3MAOBKCNH2 | |
| SCHEMBL19259647 | 0.79 | LOXL2 (0.74) | LOXL2MAOAAOC3KCNH2LOXL3 | |
| SCHEMBL29971329 | 0.79 | LOXL2 (0.64) | LOXL2MAOAAOC3MAOBKCNH2 | |
| SCHEMBL19259856 | 0.74 | LOXL2 (0.77) | LOXL2MAOAAOC3MAOBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416956-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | The Institute of Cancer Research : The Royal Cancer Hospital (GB) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017141049-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-08-24 | — | — | WO | disclosed |